Amy W. Schulman
Amy W. Schulman's purchase track record
Amy W. Schulman has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/13/2025 | GUTS | $10K | +80.1% | -15.3% | +19.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Elevance Health Q3 Outlook: Premium Pressures and Sector Peer Trends. Elevance Health is preparing for its third-quarter earnings report, with analysts examining key metrics and the potential impact of lower premiums on the company's results. Broader sector news highlights peers like UnitedHealth, Centene, and Oscar Health pursuing growth and cost-saving strategies amidst shifting premium dynamics. The market is observing how these competitive and industry-wide pressures will align with Elevance Health's upcoming performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
GUTS after hours trading shows Bollinger Band breakdown. After hours trading for GUTS showed a breakdown of the Bollinger Bands and a high beta signal, suggesting increased volatility. The stock is near its support level at $0.76, with an RSI of 33.0 indicating it is not overbought. This activity may keep the price near the lower end of its 52‑week range. The market is watching how the stock reacts to this volatility.
Transaction History
| ALNY | ▲ Buy | Grant | 838 | $0 | 5/20/2026 | View on chart |
| ELV | ▲ Buy | Grant | 563 | $0 | 5/13/2026 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 11,250 | $790K | 5/13/2026 | View on chart |
| ELV | ▼ Sell | Open Market | 26 | $7K | 3/12/2026 | View on chart |
| ELV | ▲ Buy | Grant | 218 | $0 | 2/2/2026 | View on chart |
| ALNY | ▲ Buy | Grant | 775 | $0 | 5/8/2025 | View on chart |
| GUTS | ▲ Buy | Open Market | 8,550 | $10K | 3/13/2025 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 2,750 | $361K | 3/13/2025 | View on chart |
| ALNY | ▼ Sell | Open Market | 8,500 | $2.0M | 6/25/2024 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 8,500 | $1.1M | 6/25/2024 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 30,000 | $2.0M | 5/29/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 63 | $9K | 5/29/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 10,121 | $1.5M | 5/29/2024 | View on chart |
| ALNY | ▼ Sell | Open Market | 11,516 | $1.7M | 5/29/2024 | View on chart |
| ALNY | ▲ Buy | Option Exercise | 136 | $0 | 2/23/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets
Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.
Alnylam Q3 Earnings Call Set; Analysts Adjust Targets. Alnylam Pharmaceuticals is preparing to discuss its third-quarter 2026 financial results in an upcoming webcast. Ahead of this event, Citigroup and Wells Fargo maintained their ratings but lowered their price targets to $320 and $253, respectively. These adjustments occur while the stock trades near its 52-week low, reflecting a cautious market stance despite ongoing RNAi commercial momentum.